Conductance measurement circuit with wide dynamic range

A conductance measurement circuit to measure conductance of a solution under test with an output voltage proportional to conductance over a 5-decade range, i.e., 0.01 uS to 1000 uS or from 0.1 uS to 10,000 uS. An increase in conductance indicates growth, or multiplication, of the bacteria in the test solution. Two circuits are used each for an alternate half-cycle time periods of an alternate squarewave in order to cause alternate and opposite currents to be applied to the test solution. The output of one of the two circuits may be scaled for a different range optimum switching frequency dependent upon the solution conductance and to enable uninterrupted measurement over the complete 5-decade range. This circuitry provides two overlapping ranges of conductance which can be read simultaneously without discontinuity thereby eliminating range switching within the basic circuitry. A VCO is used to automatically change the operating frequency according to the particular value of the conductance being measured, and comparators indicate which range is valid and also facilitate computer-controlled data acquisition. A multiplexer may be used to monitor any number of solutions under test continuously

Exploring root rot pathogens in wheat-pea rotations in Kansas

In 2018, over 277,000 bushels of wheat were produced on 7.7 million acres of land in Kansas alone. Based on the price of wheat by the end of 2018, this accounted for $1.44 million. This wheat is normally rotated with soybeans or fallow, but recent interest has arisen regarding the growth of peas in northern Kansas. As of 2019, there are both research and commercial growing operations underway. Many plant diseases have been especially prevalent during the summer because of the high rainfall and heat. In order to assess the severity of pea disease in Kansas, as well as explore potential interconnectivity between wheat and pea pathogens, a survey was conducted, and efforts were made to isolate and culture fungal pathogens of both wheat and pea

First Time Detection Of Brome Mosaic Virus Associated With Other Wheat Viruses In Kansas Wheat Using Nanopore Sequencing

Kansas wheat production has been threatened by Wheat streak mosaic complex of three viruses including Wheat streak mosaic virus (WSMV). Triticum mosaic virus (TriMV), and High Plains wheat mosaic emaravirus (HPWMOV). In 2017. Kansas wheat producers lost 19.2 million bushels of wheat worth $76.8 million due to wheat streak mosaic. Infection of a single plant with multiple viruses is common in wheat fields. Other common wheat viruses have been recorded from Kansas but not the Brome mosaic virus (BMV) Diagnosis of virus like symptoms in plants has been mostly dominated by targeted-specific methods with known antibodies, primers, and probes. These targeted methods identify only already known viruses and virus combinations Next generation sequencing techniques such a Nanopore sequencing technology has great potential for identifying novel and multiple potential plant pathogens in a single analysis. Reliable diagnostic methods are needed to identify the risks in plant health to develop appropriate plant protection strategies

American political affiliation, 2003–43: a cohort component projection

The recent rise and stability in American party identification has focused interest on the long-term dynamics of party bases. Liberal commentators cite immigration and youth as forces which will produce a natural Democratic advantage in the future while conservative writers highlight the importance of high Republican fertility in securing Republican growth. These concerns foreground the neglect of demography within political science. This paper addresses this omission by conducting the first ever cohort component projection of American partisan populations to 2043 based on survey and census data. A number of scenarios are modeled, but, on current trends, we predict that American partisanship will shift much less than the nation’s ethnic composition because the parties’ age structures are similar. Still, our projections find that the Democrats gain two to three percentage points from the Republicans by 2043, mainly through immigration, though Republican fertility may redress the balance in the very long term

High Levels of Human Immunodeficiency Virus Type 1 in Blood and Semen of Seropositive Men in Sub-Saharan Africa

High levels of human immunodeficiency virus type 1 (HIV-1) replication, as reflected in HIV-1 RNA concentrations in blood and semen, probably contribute to both rapid disease progression and enhanced sexual transmission. Semen and blood were collected from 49 Malawian and 61 US and Swiss (US/Swiss) HIV-1.seropositive men with similar CD4 cell counts and no urethritis or exposure to antiretroviral drugs. Median seminal plasma and blood plasma HIV-1 RNA concentrations were > 3-fold (P = .034) and 5-fold (P = .0003) higher, respectively, in the Malawian men. Similar differences were observed in subsets of the Malawian and US/Swiss study groups matched individually for CD4 cell count (P = .035 and P <.002, respectively). These observations may help explain the high rates of HIV-1 sexual transmission and accelerated HIV-1 disease progression in sub-Saharan Afric

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted therapies are being investigated as potentially more efficacious and tolerable alternatives for this multiply-relapsing disease. Based on promising activity with rituximab and lenalidomide in previously untreated follicular lymphoma (overall response rate [ORR] 90%-96%) and ibrutinib in relapsed disease (ORR 30%-55%), the Alliance for Clinical Trials in Oncology conducted a phase 1 trial of rituximab, lenalidomide, and ibrutinib. Previously untreated patients with follicular lymphoma received rituximab 375 mg/m 2 on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 4, 6, 8, and 10; lenalidomide as per cohort dose on days 1 to 21 of 28 for 18 cycles; and ibrutinib as per cohort dose daily until progression. Dose escalation used a 3+3 design from a starting dose level (DL) of lenalidomide 15 mg and ibrutinib 420 mg (DL0) to DL2 (lenalidomide 20 mg, ibrutinib 560 mg). Twenty-two patients were enrolled; DL2 was determined to be the recommended phase II dose. Although no protocol-defined dose-limiting toxicities were reported, a high incidence of rash was observed (all grades 82%, grade 3 36%). Eleven patients (50%) required dose reduction, 7 because of rash. The ORR for the entire cohort was 95%, and the 12-month progression-free survival was 80% (95% confidence interval, 57%-92%). Five patients developed new malignancies; 3 had known risk factors before enrollment. Given the increased toxicity and required dose modifications, as well as the apparent lack of additional clinical benefit to the rituximab-lenalidomide doublet, further investigation of the regimen in this setting seems unwarranted. The study was registered with www.ClinicalTrials.gov as #NCT01829568